Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: Maternal immunization with oxidized low-density lipoprotein prior to pregnancy prevents pathogenic in utero programming by gestational hypercholesterolemia, but it is unknown whether gestational hypercholesterolemia and maternal immunization affect similar pathways.
Study Design: A lipidomic approach was used for unbiased plasma eicosanoid profiling in adult offspring of immunized and nonimmunized normocholesterolemic or hypercholesterolemic rabbit mothers.
Results: Gestational hypercholesterolemia was associated with increased levels of some eicosanoids formed by the cyclooxygenase and 12-lipoxygenase pathways only (including thromboxane B2, prostaglandin [PG] F2α, PGE2, and PGD2). Immunization of hypercholesterolemic or normocholesterolemic mothers reduced 9 of 14 eicosanoids of the cyclooxygenase pathway, 21 of 23 eicosanoids of the 5- and 12-lipoxygenase pathways (eg, 5-hydroxyeicosatetraenoic acid, hepoxilin B3, 12-hydroxyeicosatetraenoic acid), 8 of 19 eicosanoids of the cytochrome P-450 pathway, and all metabolites of the nonenzymatic pathway.
Conclusion: Maternal immunization not only counteracts in utero programming by gestational hypercholesterolemia but reduces a broad range of eicosanoid modulators of immunity and inflammation in offspring.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175501 | PMC |
| http://dx.doi.org/10.1016/j.ajog.2011.03.044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Personalized Medicine Approach is Best for Patients with Homozygous Familial Hypercholesterolemia.
Med Res Arch
December 2024
Department of Genomic Health, Geisinger, Danville, PA, USA.
Homozygous familial hypercholesterolemia (HoFH) is an autosomal semi-dominant condition characterized by biallelic pathogenic variants impacting low-density lipoprotein receptor (LDLR) function. Affected individuals have severely elevated LDL cholesterol, early onset atherosclerotic heart disease and/or aortic stenosis, and characteristic clinical findings. While the cause is known and diagnosis is relatively simple, real-world HoFH care presents many complexities, including genetic heterogeneity and the diverse personal and social circumstances that influence care.
View Article and Find Full Text PDFLDLR H3K27ac in PBMCs: An Early Warning Biomarker for Hypercholesterolemia Susceptibility in Male Newborns Treated with Prenatal Dexamethasone.
Toxics
July 2025
Department of Pharmacology, School of Basic Medical Science, Wuhan University, Wuhan 430071, China.
Dexamethasone, widely used as an exogenous glucocorticoid in clinical and animal practice, has recently been recognized as an environmental contaminant of concern. Existing evidence documents its ability to induce persistent dyslipidemia in adult offspring. In this study, plasma cholesterol levels in male rats exposed to dexamethasone prenatally (PDE) were increased.
View Article and Find Full Text PDFObjective: To evaluate the incidence of expanded carrier screening (ECS) results with possible clinical implications on patient health and/or pregnancy-related treatment planning.
Design: Single academic center, retrospective, cohort study.
Subjects: 3,136 patients underwent ECS between January 2018 and December 2020.
Impact of placenta-derived extracellular vesicles on endothelial function in supraphysiological maternal hypercholesterolemia.
Placenta
August 2025
Facultad de Ciencias, Universidad San Sebastián, Santiago, 7510157, Chile. Electronic address:
Unlabelled: Maternal physiological hypercholesterolemia (MPH; total cholesterol (TC)≤280 mg/dL) occurs during pregnancy to support fetal growth. When TC exceeds this threshold, this condition is recognized as maternal supraphysiological hypercholesterolemia (MSPH), which is associated with endothelial dysfunction in the maternal and fetoplacental vasculature. Placenta-derived extracellular vesicles (EVs), which mediate intercellular communication during pregnancy, may contribute to MSPH by affecting endothelial cells.
View Article and Find Full Text PDFStatin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study.
Eur Heart J
August 2025
PharmacoEpidemiology and Drug Safety Research Group, University of Oslo, Oslo, Norway.
Background And Aims: Statins and other lipid-modifying agents (LMAs) have traditionally been contraindicated during pregnancy due to concerns about harmful fetal effects; however, the risks associated with exposure to statins and other LMAs in human pregnancies remain unclear. Therefore, this study aimed to examine the associations between statin and LMA exposure in pregnancy and congenital malformations in offspring, while updating a 2022 meta-analysis with the results from the present study.
Methods: National registry data were linked for all pregnant women in Norway in 2005-18.